Alternative MED (aMED) score will be calculated using the Food Frequency Questionnaire (FFQ). aMED scores range from 0 (nonadherence) to 9 (perfect adherence)
| Group | Value | 95% CI |
|---|---|---|
| Mobile Health | 2.63 | ± 2.0 |
| Usual Care | -0.29 | ± 1.38 |
Last reviewed · How we verify
Mobile Health Intervention to Support Healthful Diet
NA trial testing Mobile app in Frailty in 15 participants. Completed in 28 February 2023.
| Lead sponsor | University of Washington |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 15 |
| Start date | 1 January 2022 |
| Primary completion | 28 February 2023 |
| Estimated completion | 28 February 2023 |
| Sites | 1 location across United States |
University of Washington
65 and older, any sex, with Frailty. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Alternative MED (aMED) score will be calculated using the Food Frequency Questionnaire (FFQ). aMED scores range from 0 (nonadherence) to 9 (perfect adherence)
| Group | Value | 95% CI |
|---|---|---|
| Mobile Health | 2.63 | ± 2.0 |
| Usual Care | -0.29 | ± 1.38 |
Insulin resistance scores, homeostatic model (HOMA-IR) was calculated with the following formula: fasting plasma glucose (in mmol/L) X fasting plasma insulin (in lU/mL) divided by 22.5. Higher score indicates worse insulin resistance. Typically, a HOMA-IR value of less than 1 is considered normal, indicating low insulin resistance.
| Group | Value | 95% CI |
|---|---|---|
| Mobile Health | -0.18 | ± 0.72 |
| Usual Care | 0.1 | ± 0.74 |
MedD knowledge will be assessed using the Mediterranean Diet Nutrition Knowledge (MDNK) Questionnaire. The total scores range from 0 to 30. Higher score higher knowledge
| Group | Value | 95% CI |
|---|---|---|
| Mobile Health | 2.0 | ± 2.33 |
| Usual Care | -1.14 | ± 1.95 |
Questionnaire, 7 items rated on a 5-point scale (strongly agree 5; strongly disagree 1). Higher score more positive outcome expectations. The total scale ranges from 7 to 35
| Group | Value | 95% CI |
|---|---|---|
| Mobile Health | 1.5 | ± 5.26 |
| Usual Care | 1.0 | ± 3.74 |
Questionnaire, 6 items rated on a 5-point scale (strongly agree 5; strongly disagree 1). Higher score more negative outcome expectations. The total score ranges from 30 to 6
| Group | Value | 95% CI |
|---|---|---|
| Mobile Health | -3.25 | ± 3.62 |
| Usual Care | -0.43 | ± 1.9 |
Questionnaire, 2 items rated on a 5-point scale (strongly agree 5; strongly disagree 1). Higher score more self-regulation. The total scale ranges from 10 to 2
| Group | Value | 95% CI |
|---|---|---|
| Mobile Health | -0.13 | ± 1.25 |
| Usual Care | -1.86 | ± 3.13 |
Visual analog scale (VAS), 6 items using a 10-point scale. Higher values more self-efficacy. The total score ranges from O to 60
| Group | Value | 95% CI |
|---|---|---|
| Mobile Health | 1.75 | ± 10.59 |
| Usual Care | -2.0 | ± 10.21 |
Questionnaire, 2 items rated on a 5-point scale (strongly agree 5; strongly disagree 1). Higher score more social support. The total score ranges from 10 to 2
| Group | Value | 95% CI |
|---|---|---|
| Mobile Health | 1.5 | ± 1.41 |
| Usual Care | -0.14 | ± 2.19 |
Short Physical Performance Battery (SPPB) is a composite measure assessing walking speed, standing balance, and sit-to-stand performance. The three tests are summed to give a total score, with a maximum of 12 and minimum of 0. Higher score higher function
| Group | Value | 95% CI |
|---|---|---|
| Mobile Health | 1.5 | ± 1.2 |
| Usual Care | 0.14 | ± 0.9 |
BMI in units
| Group | Value | 95% CI |
|---|---|---|
| Mobile Health | -0.83 | ± 0.95 |
| Usual Care | -0.16 | ± 0.65 |
This will be a pilot clinical trial to evaluate preliminary efficacy of a newly designed mobile intervention designed to support healthy eating in old people. The main scientific premise of this project is that mobile approaches are feasible for behavioral and metabolic improvements in the population of people 65+ with mild-to-moderate frailty. Specific Aim of this project is to describe feasibility, acceptability and initial efficacy of the newly designed mobile intervention in a pilot RCT. The pilot RCT, comparing usual care to usual care plus mobile intervention, will provide data on the sensitivity of outcome measures and estimated effect size to inform a larger RCT. Primary outcomes for the pilot RCT will include change in adherence to Mediterranean diet (MedD) score, change in insulin sensitivity measures, feasibility and acceptability. Secondary outcomes include MedD knowledge, self-efficacy, outcome expectation, self-regulation, social support, platform use and anthropometric and functional measures.
1 peer-reviewed publication reference this trial (live from Europe PMC):
Verify or expand the search:
Trials testing the same drug.
Currently open trials in the same condition.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05236712.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing